PAVmed Inc. shares rose by 5.68% as the stock crossed above the 5-day SMA, reflecting positive market sentiment.
The increase in stock price follows the announcement that PAVmed's subsidiary, Lucid Diagnostics, secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, significantly enhancing access to over 9 million veterans. This contract not only strengthens PAVmed's competitive position in the healthcare market but also simplifies procurement for VA hospitals through pre-negotiated pricing aligned with Medicare standards. The strong clinical evidence supporting EsoGuard is expected to facilitate further integration into standard clinical practice.
This contract is a significant milestone for PAVmed, as it enhances the company's market share in early cancer detection and reflects growing investor confidence in its growth potential.
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 17.00 USD with a low forecast of 17.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 17.00 USD with a low forecast of 17.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.120
Low
17.00
Averages
17.00
High
17.00
Current: 8.120
Low
17.00
Averages
17.00
High
17.00
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$19 → $20
2025-04-21
Reason
Ascendiant Capital
Edward Woo
Price Target
$19 → $20
AI Analysis
2025-04-21
Maintains
Strong Buy
Reason
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
